What is SNTI's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SNTI?

P/E (TTM) is n/a and 52-week range is $0.29 to $2.88 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SNTI figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SNTI?

The company profile lists revenue (TTM) near $56K, net income (TTM) near $-3.20B, EPS (TTM) near $-1.76 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Senti Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 31.1M shares outstanding, ISIN US8169441024 when available from company profile and filing metadata.

Senti Biosciences Inc

$SNTI

Health Care · Biotechnology

IR Run Scenarios

$0.31

-2.27%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Senti Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 39 full-time employees. The company went IPO on 2021-05-26. Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Employees

Website

www.sentibio.com

IPO

2021-05-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)